Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trimeris and Roche extend research agreement
The extension of the agreement governs the joint research efforts by US biopharmaceutical company Trimeris and Roche on next generation fusion inhibitor (NGFI) peptides, first signed by the
The extension of the agreement governs the joint research efforts by US biopharmaceutical company Trimeris and Roche on next generation fusion inhibitor (NGFI) peptides, first signed by the
“After evaluating the results of our earlier phase II clinical trial in 253 patients and after conducting additional laboratory work, we concluded that a reformulation of our original
Dyax will also perform funded research on certain targets of Serono to identify therapeutic antibodies. Under the terms of the agreement, Dyax receives technology license fees and full-time
DCVax-LB is an extension of the DCVax personalized cancer vaccine that has already shown significant delay in disease progression and in extension of survival in clinical trials in
The collaboration involves four global research sites of Boehringer Ingelheim. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation
The PLA2 inhibitors were developed by Lilly and Shionogi as part of their collaboration and is designed to treat acute chest syndrome (ACS) in life-threatening diseases such as
The study treated women with locally advanced breast cancer. According to the company, results were better than what would be expected from chemotherapy treatment alone. Complete tumor removal
Geron acquired rights to this technology from the Roslin Institute in 1999 and subsequently initiated patent interferences with conflicting patents held by the University of Massachusetts. The US
Mundipharma will have exclusive rights to market Flutiform in Europe and other territories outside North, Central and South America, with an option to negotiate for exclusive rights in
Clinical trials have been completed evaluating the efficacy and safety of Humira in a range of moderate-to-severe Crohn's disease patients. In these trials, Humira demonstrated statistical significance in